First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) Stock Price Down 0.8% - Should You Sell?

Key Points

• Price drop: Shares fell 0.8% to GBX 1,802.81 on Thursday, with only about 25 shares traded — a 97% decline versus the average daily volume of 877.
• Technicals and valuation: The ETF’s 50-day moving average is GBX 1,876.94 and the 200-day is GBX 1,834.80; market capitalization is £739.54 million and the reported PE is a negative -1,638.92.
• Reporting error: The article’s company profile appears incorrect, describing Forbidden Technologies plc (Blackbird) rather than the First Trust NYSE Arca Biotechnology UCITS ETF.

Shares of First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT - ) dropped 0.8% during mid-day trading on Thursday . The company traded as low as GBX 1,802.81 and last traded at GBX 1,802.81. Approximately 25 shares were traded during trading, a decline of 97% from the average daily volume of 877 shares. The stock had previously closed at GBX 1,817.20.

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Trading Down 0.8%

The firm has a 50 day moving average price of GBX 1,876.94 and a 200 day moving average price of GBX 1,834.80. The stock has a market capitalization of £739.54 million and a PE ratio of -1,638.92.

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Company Profile

Forbidden Technologies plc develops and owns cloud-based video technology in the United Kingdom, North America, and internationally. It offers Forscene, a cloud based video post-production and publishing platform with various applications, such as editing, adding closed caption, graphics, metadata fast, remote viewing, collaboration, and publishing content. The company operates under the brand name of Blackbird. The company was founded in 1998 and is based in London, the United Kingdom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.